Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.36 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.36 |
| ▸ | ITGAL | P20701 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10284783 | 0.80 | ALDH1A1 (0.40) | SMN1; SMN2GAAKMT2AKDM4EALDH1A1 | |
| SCHEMBL18159806 | 0.72 | RARA (0.40) | SMN1; SMN2GAAKMT2ANOTUMKDM4E | |
| SCHEMBL19852199 | 0.72 | ITGB2 (0.50) | SMN1; SMN2GAAKMT2ANOTUMKIF11 | |
| SCHEMBL30403463 | 0.70 | ITGB2 (0.43) | SMN1; SMN2GAAKMT2ALDHAITGB2 | |
| SCHEMBL27999909 | 0.70 | AKR1B1 (0.41) | SMN1; SMN2GAAKMT2AKDM4ELDHA | |
| SCHEMBL26150559 | 0.70 | SMN1; SMN2 (0.39) | SMN1; SMN2GAAKMT2ANOTUMKIF11 | |
| SCHEMBL2632863 | 0.70 | ITGB2 (0.46) | SMN1; SMN2GAAKMT2AITGB2ICAM1 | |
| SCHEMBL263371 | 0.70 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL10754920 | 0.69 | ITGB2 (0.38) | SMN1; SMN2GAAKMT2ANOTUMKIF11 | |
| SCHEMBL10759714 | 0.69 | KMT2A (0.39) | SMN1; SMN2GAAKMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010256-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB | 2012-01-12 | — | — | US | disclosed |
| US-20110082107-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | AMGEN INC. | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082107-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD3B1, HSD17B1 | SMN1; SMN2 2510/4885GAA 393/4885KMT2A 3049/4885 |
| US-20120010256-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD3B1, HSD17B1 | SMN1; SMN2 2510/4885GAA 393/4885KMT2A 3049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.